"30 million Americans are affected by chronic kidney disease and most do not even know they have it. However, 96% of those with early kidney disease (stages 1 and 2) don't even know they have CKD. The number of Americans with chronic kidney disease is higher than previously estimated and affects 15% of the U.S. adult population, according to new data analyzed by the Centers for Disease Control and Prevention. One in seven American adults, or 30 million people, are estimated to have CKD. An estimated 15% of Hispanics have CKD and Hispanics are 35% more likely than non-Hispanics to progress to ESRD.
Canagliflozin reduces risk for CVD, kidney disease in patients with type 2 diabetes
Within the cohort, 9,734 participants completed the trials; mean follow-up for both trials was 188.2 weeks, with a longer follow-up period in the CANVAS study (mean, 295.9 weeks). In a randomized, double blind, placebo-controlled trial conducted across 30 countries, researchers also noted that participants assigned canagliflozin (Invokana, Janssen) were twice as likely to experience an amputation, primarily at the toe or metatarsal, compared with those receiving placebo. Researchers randomly assigned participants in CANVAS to receive either 100 mg or 300 mg canagliflozin or placebo; participants in CANVAS-R received an initial dose of 100 mg canagliflozin daily with an optional increase to 300 mg at week 13, or matching placebo. At baseline, 65.6% of participants had a history of CVD, 22.6% had microalbuminuria and 7.6% had macroalbuminuria. Follow-up occurred every 3 months for the first year and at 6-month intervals thereafter, with follow-up by telephone between in-person appointments.collected by :Lucy William
No comments:
Post a Comment